Civilization Ventures
VC Fund
San Francisco, United States
Civilization Ventures is a VC fund in San Francisco focused on Biotechnology and Health Care. Civilization Ventures invests in visionary founders that are leading the future of health tech and biology-driven innovation. We aim to be the first check and lead investor in highly disruptive companies across digital health, synthetic biology, diagnostics, 3D (bio) printing, and AI/ software-enabled health tech. Our team comprises serialentrepreneurs and industry thought leaders who work tirelessly to help each of our portfolio companies succeed.
- Total investments:
- 76
- Last investment:
- Lead investor:
- 3%
- Fund size:
- $35M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Civilization Ventures invests in
Stages Civilization Ventures invests in
Countries Civilization Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.8M–$16M
- Series A
- $8.1M–$30M
- Series B
- $24M–$144M
Investment Focus
Industry
- Biotechnology 32 (42%)
- Health Care 27 (36%)
- Medical 15 (20%)
- Life Science 9 (12%)
- Therapeutics 8 (11%)
Stage
- Seed 27 (36%)
- Series A 21 (28%)
- Series B 5 (7%)
- Pre-Seed 4 (5%)
- Series C 4 (5%)
Country
- United States 45 (59%)
- United Kingdom 2 (3%)
- Brazil 1 (1%)
- Cayman Islands 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Shahram Seyedin-Noor
Founder and General Partner
|
Founder and General Partner | Total investments: 5 | Find email | |
|
Zoya Khan
Analyst
|
Analyst | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Rinascera Therapeutics
|
Rinascera Therapeutics is a clinical-stage biotechnology company that develops systemic and topical therapies targeting the biological causes of rare genetic skin diseases. Its current focus is advancing acquired clinical drug assets to treat inherited skin disorders like Gorlin Syndrome and Dystrophic Epidermolysis Bullosa (DEB). | Seed / Jul 16, 2026 | |
10x Science
|
10x Science offers an AI software that analyzes protein data to characterize molecular structures and support biopharmaceutical research. | $4.8M / Seed / Apr 22, 2026 | |
Tacit Therapeutics
|
Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California. | $19M / Series A / Mar 09, 2026 | |
Trial Library
|
Trial Library is an oncology clinical trials company. | $10M / Series A / Dec 02, 2025 | |
Curve Biosciences
|
Curve Biosciences is a biotechnology company focused on enhancing chronic disease care through precision medicine. With a team led by experts such as Nathan Hunkapiller, PhD, as Chief Scientific Officer, and Chuba Oyolu, PhD, as Chief Technology Officer, the company is at the forefront of research and development in the biotech field. CurveBiosciences aims to leverage scientific advancements to provide targeted solutions for chronic diseases, emphasizing the importance of precision in treatment approaches. The company operates within the biotechnology industry and is dedicated to improving patient outcomes through innovative research. | $40M / Series A / Oct 29, 2025 | |
Iantrek
|
Iantrek develops technology for minimally invasive microinvasive glaucoma surgery. It was founded in 2019 and is based in White Plains, New York. | $42M / Series C / Aug 20, 2025 | |
Tahoe Therapeutics
|
Tahoe Therapeutics develops AI-powered tools to simulate human cell responses and guide drug discovery. It operates a platform called Mosaic that produces large-scale single-cell datasets detailing how drug molecules interact with diverse patient cells, with initial applications in oncology. It open-sources its Tahoe-100M dataset, comprisinghundreds of millions of single-cell profiles, to train AI models that build virtual cell models for therapeutic insights. A recent funding round enabled the creation of an even larger dataset, targeting one billion cell datapoints and one million drug-patient interactions, designed to fuel next-generation precision medicines | $30M / Series A / Aug 11, 2025 | |
Antheia
|
Antheia is unlocking the medicinal power of nature. Its synthetic biology platform surpasses the limits of conventional drug discovery and manufacturing through a novel approach to whole-cell engineering —reconstructing complex molecules in yeast to bring to market next-generation plant-inspired medicines. | $56M / Series C / Jun 03, 2025 | |
|
Integrated Biosciences
|
Integrated Biosciences is the first company in history to be able to virtually stress cells. | $17.2M / Seed / Oct 03, 2024 | |
SyntaxBio
|
SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention. | Seed / Sep 17, 2024 | |
| See all 76 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Featured in Investor Lists
Recommended lists
FAQ
What does Civilization Ventures invest in?
Civilization Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 76 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Civilization Ventures's check size?
Civilization Ventures typically joins rounds of $1.8M–$16M at Seed, $8.1M–$30M at Series A and $24M–$144M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Civilization Ventures participates in.
How do I contact Civilization Ventures?
Public channels for Civilization Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Civilization Ventures?
The team at Civilization Ventures includes Shahram Seyedin-Noor (Founder and General Partner) and Zoya Khan (Analyst). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
